Alexion Pharmaceuticals (NASDAQ:ALXN) Earning Somewhat Positive Media Coverage, Analysis Finds

Headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.1817736510498 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern’s scoring:

ALXN has been the topic of several recent analyst reports. Cowen and Company reissued an “outperform” rating and set a $122.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, July 3rd. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $165.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Morgan Stanley reaffirmed an “overweight” rating and issued a $153.00 price target (up from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Leerink Swann raised their price target on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $158.00 price target (up from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $154.60.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 128.62 on Friday. The company has a 50-day moving average of $141.58 and a 200 day moving average of $128.29. The firm has a market cap of $28.71 billion, a P/E ratio of 55.78 and a beta of 1.39. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the prior year, the business posted $1.23 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. Equities research analysts anticipate that Alexion Pharmaceuticals will post $5.62 earnings per share for the current fiscal year.

In other news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the transaction, the executive vice president now directly owns 26,704 shares in the company, valued at $3,738,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Insiders have sold 17,190 shares of company stock valued at $2,433,669 in the last ninety days. 4.35% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/alexion-pharmaceuticals-alxn-receives-media-sentiment-score-of-0-10.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply